236L細胞

數量： 大量

細胞形態： **樣

**類型： IgG1; kappa light chain

ATCC Number： HB-12593?

運輸方式： 凍存運輸

生長狀態： 懸浮生長

是否是腫瘤細胞： 0

物種來源： 小鼠

Designations: 236L

Depositors: ICOS Corporation

Isotype: IgG1; kappa light chain

236L細胞Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)

Morphology: lymphoblast

Cellular Products: immunoglobulin; monoclonal antibody; against alphaD subunit of rat beta2 236L細胞(alphaDbeta2) integrin

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Comments: Animals were immunized with purified rat alphaD subunit. [56177]

Spleen cells were fused with NS-1 mouse myeloma cells.

This antibody is specific for the rat subunit integrin alphaD.

It may be used to inhibit inflammation at the site of a central nervous system injury.

Propagation: 236L細胞ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate, 85%; heat-inactivated fetal bovine serum, 15%

Temperature: 37.0°C

Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)

Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.

Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.

Preservation: Culture medium supplemented with an additional 50% heat-inactivated fetal bovine serum and 10% DMSO

References: 56177: Gallatin WM, Van der Vieren M. Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies. US Patent 6,251,395 dated Jun 6 2001

57779: Mabon PJ, et al. Inhibition of monocyte/macrophage migration to a spinal cord injury site by an antibody to the integrin alphaD: a potential new anti-inflammatory treatment. Exp. Neurol. 166: 52-64, 2000. 236L細胞PubMed: 11031083